Registry series: Renal Cell Carcinoma

Record number: 
315
Adverse Occurrence type: 
MPHO Type: 
Estimated frequency: 
(Council of Europe, 2022): To provide valid histological staging, complete tumour resection (R0) is required for acceptance of all organs; additionally, tumour-free margins are a prerequisite for transplant of the affected kidney. Paraffin section is superior to frozen section for the assessment of such biopsies. The contralateral kidney should always be examined for synchronous RCC (5 % of patients). RCC < 1 cm (stage T1a AJCC 8th edn) and WHO/ISUP grade I/II (Fuhrman grade I/II) can be considered minimal-risk for transmission; RCC 1-4 cm (stage T1a AJCC 8th edn) and WHO/ISUP grade I/II (Fuhrman grade I/II) are considered low-risk; RCC > 4-7 cm (stage T1b AJCC 8th edn) and WHO/ISUP grade I/II (Fuhrman grade I/II) are considered intermediate-risk; RCC > 7 cm (stage T2 AJCC 8th edn) and WHO/ISUP grade I/II (Fuhrman grade I/II) are considered high-risk; RCC with extension beyond the kidney (stages T3/T4 AJCC 8th edn) is considered a contraindication to transplant; All RCC with WHO/ISUP grade III/IV (Fuhrman grade III/IV) are considered high-risk for transmission; Contralateral kidneys and other organs that are un¬involved in carcinoma are considered to represent minimal risk for transplantation when the RCC in the involved kidney is 4 cm or less and WHO/ISUP grade I-II. In all cases, follow-up surveillance is desirable. RCC in the donor history: The transmission risk of treated RCC depends on the histological type of tumour [159] and its recurrence-free follow-up period. In general, in the first 5 years after initial diagnosis, risk categories correspond to those stated above (RCC diagnosed during donor procurement) if there is no suspicion of tumour recurrence in the donor. After this time, the risk of advanced stages may decrease.
Time to detection: 
<11, <14 months (2 cases)
Alerting signals, symptoms, evidence of occurrence: 
Lung case: alerting signals not detailed. Tumour showed histologic evidence of vascular invasion. Reciepient died of lung and liver metastases at 11 months after transplantation.
Demonstration of imputability or root cause: 
Assessment of disease transmission studied by biopsy confirmatory with comparison of the recipient cancer to the primary donor tumour or in some cases genetic allelic analysis (not specified in this particular case).
Groups audience: 
Suggest new keywords: 
heart transplant
lung transplant
deceased donor
malignancy
registry series
Renal cell carcinoma
Suggest references: 
AAA
Expert comments for publication: 
Two cases of RCC transmission in total of 5 donor RCC cases reported as part of Penn.Cincinnati Registry report of tumor transmission in cardiothoracic recipients (2001).